COMP <GO>
GMED vs LLY // OPERATING MARGIN
Globus Medical Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: GMED 5
— LLY 9
▲ OPERATING MARGIN LEADER: LLY
LAST: $78.05 (-5.86%) • MKT CAP: $11.13B
operating-margins
16.30%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
operating-margins
40.21%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GMED VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GMED | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.40% | 83.64% | -16.24 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.70% | 32.36% | -23.66 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.6x | 36.4x | -18.82 | GMED | /valuation <GO> |
| Free Cash Flow Yield | 5.29% | 2.30% | +2.99 | GMED | /fcf-yield <GO> |
| Operating Margin ACTIVE | 16.30% | 40.21% | -23.91 | LLY | /operating-margins <GO> |
| Net Profit Margin | 18.30% | 31.90% | -13.60 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 16.70% | 45.51% | -28.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.74 | 9.29 | +1.45 | GMED | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.77% | +0.33 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.0 | 77.9 | -28.85 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.51 | +0.56 | GMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 26.3x | -8.85 | GMED | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.13B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GMED REV | LLY REV | GMED GROSS % | LLY GROSS % | GMED FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.94B | $65.18B | 67.4% | 83.0% | $588.8M | $16.81B |
| FY 2024 | $2.52B | $45.04B | 58.9% | 81.3% | $405.2M | $8.82B |
| FY 2023 | $1.57B | $34.12B | 44.0% | 79.3% | $172.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GMED // BETA 1.07
LLY // BETA 0.51